Data from this new study suggest that tailoring induction therapy for acute myeloid leukemia (AML) based on cytarabine pharmacogenomic 10–single-nucleotide variant score could better treatment for these young patients, particularly those who are Black.
Phase 1 trial results indicate that combining inotuzumab ozogamicin with dose-adjusted EPOCH chemotherapy could offer a safe, well-tolerated, and effective treatment option for patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia or lymphoma (R/R B-ALL).
The treatment showed effectiveness in achieving local control of acute myeloid leukemia (AML) that developed in the eyes of a pediatric patient.
Interim results of the randomized, phase 3 PhALLCON trial indicate ponatinib’s benefit over imatinib in frontline treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), but questions linger about ponatinib’s long-term safety.
Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Physicians treated the patient without surgery, although they said the patient’s case is particularly challenging and treatment was ongoing at the time of the report’s writing.
Data highlight substantial improvements in outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) among older patients with acute myeloid leukemia (AML).
A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how various patient subgroups fared for complete remission (CR).
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
This new report helps clarify the ways in which the disease—and its treatment—affects the lives of children.
A case report of a patient with acute leukemia who developed chronic disseminated candidiasis revealed difficulties in diagnosing and treating the illness.
The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
Treatment resistance remains a major challenge in the treatment of acute myeloid leukemia (AML), and leveraging actionable therapeutic targets is far from straightforward.
Introducing ciprofloxacin to their institution’s empiric antimicrobial regimen for patients with AML and prolonged or recurrent neutropenic fevers appeared to reduce the risk of Bacillus cereus infection.
Developing accurate predictive models for patients with pediatric acute myeloid leukemia (AML) can close the preclinical gap in treatment for the rare disease.
The findings add complexity to questions about the long-term impact of acute lymphoblastic leukemia (ALL) therapy.
Despite the widespread practice of delaying or modifying chemotherapy treatment for patients with COVID-19, the investigators wrote that there are no clear data indicating the benefit of this practice.
Coverage from the discussion, "Cancer Genomics: The Gateway to Access and Health Equity” on the first day of Patient-Centered Oncology Care 2023.
Investigators analyzed global, national, and regional trends in acute myeloid leukemia (AML), which predominantly affects individuals aged 60 to 89 years.
Circumstantial and direct evidence, including a review of twin and backtracking studies, demonstrate potential prenatal development of acute childhood leukemias.
Most of the research suggests combination therapies might be the best option for many patients who have acute myeloid leukemia (AML).
The study may help explain why some patients are more prone to relapse following a complete response to induction therapy, as indicated by measurable residual disease (MRD) status and 2017 European LeukemiaNet (ELN) criteria.
The findings suggest patient-reported outcomes—namely fatigue—may be helpful in identifying patients at a higher risk of death and other adverse outcomes but warrant further research.
Selected coverage of acute lymphoblastic leukemia (ALL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12 2023, San Diego, California.
